US Edition6 Articles
6 Articles
Dual-target CAR T cell therapy slows growth of aggressive brain cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients.
Intracerebroventricular Bivalent CAR T Cells Targeting EGFR and IL-13Rα2 in Recurrent Glioblastoma: A Phase I Trial
Researchers reported the dose escalation and exploration phases of a Phase I trial investigating intracerebroventricular delivery of bivalent CAR T cells targeting epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL-13Rα2), or CART-EGFR-IL13Rα2 cells, in patients with EGFR-amplified recurrent glioblastoma. [Nature Medicine] AbstractPress Release
Three to four hundred people a year in the Czech Republic receive a ruthless diagnosis – aggressive brain cancer, the so-called glioblastoma. Most of them are told that they only have a few months to live. Among other things, the expensive Optune treatment gives them hope for a significant extension of their life. It costs around seven million a year. But...
Newswise
littlebytesnews.comDual-Target CAR T Cell Therapy Slows Growth of Aggressive Brain Cancer
A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.
Coverage Details
Bias Distribution
- 100% of the sources are Center
To view factuality data please Upgrade to Premium
